<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202656</url>
  </required_header>
  <id_info>
    <org_study_id>09012010-02</org_study_id>
    <nct_id>NCT01202656</nct_id>
  </id_info>
  <brief_title>Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)</brief_title>
  <official_title>G-CSF(Granulocyte Colony Stimulating Factor) and Embryo Implantation and Pregnancy Following IVF (in Vitro Fertilization)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Human Reproduction</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Reproductive Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Human Reproduction</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a trial designed to test whether granulocyte colony stimulating factor (G-CSF, Neupogen)
      can increase the rate of embryo implantation following IVF and embryo transfer. Preliminary
      data at the Center for Human Reproduction(CHR) and elsewhere suggest that intrauterine
      infusion of G-CSF can improve endometrial development and can increase implantation rates of
      embryos.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To investigate the effect of treatment with CSF on pregnancy rates in routine in
      vitro fertilization (IVF).

      Design: Double blinded crossover randomized controlled clinical trial

      Setting: Academically affiliated private infertility centers

      Subjects: Normal female IVF patients 18-38 years old, and above age 38 years, who are willing
      to be randomized to treatment.

      Interventions: Subjects receive transvaginally, utilizing an insemination catheter, a slow
      uterine lavage with G-CSF (Neupogen), 300ug (in 1 ml); controls receive saline. Patients who
      do not conceive will, after one month washout time, continue treatment in the opposite study
      arm.

      Main Outcome Measures: Implantation rate(IR) and pregnancy rates.

      Second Outcome Measures: Live birth rates and miscarriage rates.

      Statistical and Power considerations: Analysis will be by regression with IR as dependent and
      treatment as independent. Results will be adjusted by age and indices of ovarian reserve,
      such as antiMulerian Hormone (AMH). Presuming an implantation rate of 10% and anticipating a
      10% increase to 20% with treatment, 120 women, producing about 200 embryos in each study arm,
      will have to be recruited for 80% power and alpha of 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Embryo Implantation and Clinical Pregnancy Rates</measure>
    <time_frame>26 to 30 days after embryo transfer</time_frame>
    <description>Implantation rate: The number of gestational sacs noted in the endometrial cavity 26 to 30 days after embryo transfer divided by the number of embryos transferred
Clinical pregnancy:
Gestational sac with evidence of a viable pregnancy at least 28 days after embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rates</measure>
    <time_frame>Within nine months of embryo transfer</time_frame>
    <description>Live birth rates among normal infertile couples undergoing IVF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>G-CSF then Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-CSF (Granulocyte colony stimulating factor)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline then G-CSF</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>One infusion of G-CSF 300 units administered by intrauterine infusion</description>
    <arm_group_label>G-CSF then Saline</arm_group_label>
    <arm_group_label>Saline then G-CSF</arm_group_label>
    <other_name>Neupogen (Filgrastim)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intrauterine saline infusion 1 cc</description>
    <arm_group_label>G-CSF then Saline</arm_group_label>
    <arm_group_label>Saline then G-CSF</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>0.91% w/v of NaCl, about 300 mOsm/L</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women already enrolled in an IVF cycle at one of the participating institutions

        Exclusion Criteria:

          -  Sickle Cell disease

          -  Renal insufficiency

          -  Upper respiratory infection or Pneumonia

          -  Chronic Neutropenia

          -  Known Past or present malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Barad, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Gleicher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Reproduction</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Barad DH, Yu Y, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee HJ, Gleicher N. A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial thickness and clinical pregnancy rates. Fertil Steril. 2014 Mar;101(3):710-5. doi: 10.1016/j.fertnstert.2013.12.016. Epub 2014 Jan 11.</citation>
    <PMID>24424357</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>May 18, 2014</results_first_submitted>
  <results_first_submitted_qc>November 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2014</results_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Human Reproduction</investigator_affiliation>
    <investigator_full_name>David H. Barad</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Fertility Agents, Female</keyword>
  <keyword>In vitro fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients presenting for embryos transfer between October 3, 2010, and January 1, 2013, were offered participation in the trial. A total of 419 eligible patients were offered participation: Only 129 patients consented to participate in this study,(12 addtional patient participated in the thin endometrium study) and 278 declined</recruitment_details>
      <pre_assignment_details>The principal reasons for refusal to participate were ''lack of interest'' and technical difficulties in presenting in timely fashion for the treatment to the center. Women with renal disease, sickle cell disease, or a history of malignancy were considered ineligible. No consenting patient was excluded from participation for medical reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-CSF Then Saline</title>
          <description>G-CSF (Granulocyte colony stimulating factor)
G-CSF 300 units administered by trans-cervical infusion one time on day of human chorionic gonadotropin(hCG) trigger for Ovulation</description>
        </group>
        <group group_id="P2">
          <title>Saline Then G-CSF</title>
          <description>Normal Saline
Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cycle 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67">Results reported In Barad et al 2014 are combined from both G-CSF studies</participants>
                <participants group_id="P2" count="62">Results reported In Barad et al 2014 are combined from both G-CSF studies</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>CrossoverCycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18">16 ongoing pregnancies were not eligible for crossover, others chose to not have another IVF cycle</participants>
                <participants group_id="P2" count="14">14 ongoing pregnancies were not eligible for crossover, others chose to not have another IVF cycle</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>G-CSF Then Saline</title>
          <description>G-CSF (Granulocyte colony stimulating factor)
G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
then
Normal Saline
Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
        </group>
        <group group_id="B2">
          <title>Saline Then G-CSF</title>
          <description>Normal Saline
Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
then
G-CSF (Granulocyte colony stimulating factor)
G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AntiMulerian Hormone (AMH)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.07" spread="2.17"/>
                    <measurement group_id="B2" value="1.99" spread="2.38"/>
                    <measurement group_id="B3" value="2.03" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Embryo Implantation and Clinical Pregnancy Rates</title>
        <description>Implantation rate: The number of gestational sacs noted in the endometrial cavity 26 to 30 days after embryo transfer divided by the number of embryos transferred
Clinical pregnancy:
Gestational sac with evidence of a viable pregnancy at least 28 days after embryo transfer</description>
        <time_frame>26 to 30 days after embryo transfer</time_frame>
        <population>Presuming an implantation rate of 10% and anticipating a 10% increase to 20% with treatment, about 200 embryos transferred in each study arm would be needed for 80% power and alpha of 0.05.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF</title>
            <description>G-CSF (Granulocyte colony stimulating factor)
G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal Saline
Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Implantation and Clinical Pregnancy Rates</title>
          <description>Implantation rate: The number of gestational sacs noted in the endometrial cavity 26 to 30 days after embryo transfer divided by the number of embryos transferred
Clinical pregnancy:
Gestational sac with evidence of a viable pregnancy at least 28 days after embryo transfer</description>
          <population>Presuming an implantation rate of 10% and anticipating a 10% increase to 20% with treatment, about 200 embryos transferred in each study arm would be needed for 80% power and alpha of 0.05.</population>
          <units>Gestational sacs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Embryos Transferred</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Live Birth Rates</title>
        <description>Live birth rates among normal infertile couples undergoing IVF</description>
        <time_frame>Within nine months of embryo transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF</title>
            <description>G-CSF (Granulocyte colony stimulating factor)
G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal Saline
Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rates</title>
          <description>Live birth rates among normal infertile couples undergoing IVF</description>
          <units>Live Birth</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>G-CSF</title>
          <description>G-CSF (Granulocyte colony stimulating factor)
G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Normal Saline
Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study results are applicable only to women undergoing routine IVF. Most of the women in this trial had normal endometrial thickness at randomization.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David Barad</name_or_title>
      <organization>Center for Human Reproduction</organization>
      <phone>212 994-4400</phone>
      <email>dbarad@theCHR.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

